Farrerol ameliorates diabetic cardiomyopathy by inhibiting ferroptosis via miR-29b-3p/SIRT1 signaling pathway in endothelial cells

Figure 3 Farrerol treatment inhibited ferroptosis in diabetic hearts. A: RNA-sequencing was used to investigate the underlying mechanism of Farrerol on diabetic cardiomyopathy and a heatmap showed the top 20 differentially expressed genes (DEGs) between the groups; B: Kyoto Encyclopedia of Genes and Genome analysis of the top 100 DEGs between the groups; C-E: Western blot showed the changes of ferroptosis related proteins GPX4 and xCT in the four groups (n = 3); F: Relative expression of malondialdehyde in the hearts from indicated groups were determined by the commercial kit (n = 6); G: The content of Fe²⁺ in endothelial cells was assessed by the commercial kit (n = 6). ^aP < 0.05 vs NC; ^bP < 0.05 vs DCM. FA: Farrerol; DCM: Diabetic cardiomyopathy.